MCM6 Antibody (B-4): sc-55576

MCM6 Antibody (B-4) is a mouse monoclonal IgG2a antibody that detects MCM6 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MCM6, a member of the mini-chromosome maintenance (MCM) protein family, plays a crucial role in the regulation of DNA replication, ensuring that DNA is replicated only once during each cell cycle. This regulation is vital for maintaining genomic stability, as improper replication can lead to mutations and cancer. MCM6, along with MCM2, MCM3, MCM4, MCM5, and MCM7, forms a complex that exhibits helicase activity, essential for unwinding double-stranded DNA during replication. MCM6 is primarily located in the nucleus, where MCM6 is involved in the formation of the pre-replicative complex, a critical step in the initiation of DNA synthesis. MCM6 expression is tightly regulated throughout the cell cycle, peaking during the transition from the G1 to S phase, which highlights MCM6′s importance in cell proliferation and response to cellular growth signals. MCM6 interacts with various protein kinases and transcription factors, further underscoring MCM6′s role in the intricate network of cellular processes that govern DNA replication and cell cycle progression.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MCM6 Antibody (B-4) References:

1. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression.  |  Liu, Z., et al. 2018. BMC Cancer. 18: 200. PMID: 29463213
2. High MCM6 Expression as a Potential Prognostic Marker in Clear-cell Renal Cell Carcinoma.  |  Jang, NR., et al. 2021. In Vivo. 35: 299-306. PMID: 33402477
3. The DNA replication regulator MCM6: An emerging cancer biomarker and target.  |  Zeng, T., et al. 2021. Clin Chim Acta. 517: 92-98. PMID: 33609557
4. MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma.  |  Gu, Y., et al. 2021. BMC Cancer. 21: 784. PMID: 34233647
5. MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers.  |  Sadeghian, D., et al. 2022. Diagn Pathol. 17: 24. PMID: 35125121
6. MCM6 is a critical transcriptional target of YAP to promote gastric tumorigenesis and serves as a therapeutic target.  |  Wang, Y., et al. 2022. Theranostics. 12: 6509-6526. PMID: 36185598
7. MCM6 promotes intrahepatic cholangiocarcinoma progression by upregulating E2F1 and enhancing epithelial-mesenchymal transition.  |  Gao, C., et al. 2023. Carcinogenesis. 44: 279-290. PMID: 37185675
8. MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer.  |  Lei, Z., et al. 2023. Front Biosci (Landmark Ed). 28: 128. PMID: 37664925
9. Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis.  |  Wang, J., et al. 2023. Life Sci. 335: 122253. PMID: 37951536
10. Crotonylation of MCM6 enhances chemotherapeutics sensitivity of breast cancer via inducing DNA replication stress.  |  Song, H., et al. 2025. Cell Prolif. 58: e13759. PMID: 39477811

The preferred MCM6 antibody is MCM6 Antibody (H-8): sc-393618.